By Editorial TeamThe cardiac AI monitoring market is set to explode, projected to jump from $2.2 billion in 2026 to a massive $14.8 billion by 2033. This kind of growth has obviously pulled in a ton of investment and a flood of new solutions. But if you’re a procurement specialist or a clinical evaluator, you’re the one stuck trying to make sense of it all, especially the regulatory mess around FDA clearance. That “FDA-cleared” claim seems simple, but it hides a complicated reality: what, specifically, has been cleared, and what hasn’t? Figuring that out is everything for proper due diligence, assessing your risk, and making sure the tech is safe and actually works in a clinical setting.
The Multifaceted Nature of FDA Clearance in Cardiac AI
The term “FDA-cleared” isn’t some magic wand waved over an entire product, especially not in a field moving as fast as cardiovascular AI. The main path, the 510(k) clearance, is all about the FDA confirming “substantial equivalence” to a device that’s already on the market (a predicate device) for a very specific use. This means a company might get one clearance for a piece of hardware, a completely separate one for a diagnostic algorithm, and maybe, if they’re lucky, a broader one for a software platform. These are all different submissions with their own limits. Anyone buying this tech has to get past the marketing headline and read the fine print on each clearance. What does this mean for AI cardiac monitoring? Think about it: a device that just captures an ECG signal might be cleared, but the AI algorithm that actually interprets that signal to find a problem almost certainly needs its own, separate clearance. This is especially true if the AI is making a diagnostic call. If the AI is meant for a medical purpose and it works on its own without being tied to specific hardware, it’s what the FDA calls Software as a Medical Device (SaMD). A lot of the new cardiac AI products are SaMD, and they have their own unique regulatory journey.
Case Study: AliveCor, Differentiating Hardware from Algorithm Clearance
AliveCor is a perfect example of how these FDA clearances can be layered. The company is famous for its KardiaMobile ECG devices that let you take a medical-grade ECG with your smartphone. The hardware itself, the little device you touch, has its own FDA clearances for recording specific types of ECGs. But that’s only half the story. AliveCor has also gone out and gotten separate clearances for the AI algorithms that analyze those ECGs. For example, their KAI 12L clearance, as of January 2026, is specifically for the AI algorithm that works with their Kardia 12L ECG hardware. The clearance isn’t just for the hardware, it’s for the algorithm’s ability to spot certain heart conditions from the 12-lead ECG data. The hardware gets the data, but the AI provides the interpretation, and they were cleared separately. If you’re evaluating AliveCor, you need to know that “FDA-cleared” applies to both parts, but each has its own defined scope. FDA 510(k) database for AliveCor clearances
Case Study: Eko Health, Software Algorithms Layered on Stethoscope Hardware
Eko Health gives us another great look at this layered approach, this time with their digital stethoscopes and the AI that goes with them. Eko’s main products are high-tech stethoscopes that capture and amplify heart and lung sounds, and this hardware has FDA clearance. But what’s interesting is that Eko has also developed and cleared specific software algorithms that work with these stethoscopes. For instance, their EMAS (Eko Murmur Analysis Software) and EFAST (Eko Fibrillation Analysis Software) are totally separate clearances. These cover specific algorithms for detecting heart murmurs and atrial fibrillation. These algorithms are essentially “layered” on top of the cleared stethoscope hardware. When Eko says its products are “FDA-cleared,” they’re talking about both the physical device and these specific AI software components, each of which had to go through its own regulatory process. It shows how one company can hold clearances for very different things (a device and an algorithm), and that you have to unpack the “FDA-cleared” claim, not just take it at face value.
Hello Heart: A Clear Line Between Cleared Device and Non-Cleared App/AI
If you want a really clear dividing line between device and software clearance, look at Hello Heart. They offer a digital program for managing cardiovascular disease that uses a smartphone app and a blood pressure monitor. The Hello Heart Monitor, the physical cuff they send to users, is an FDA-cleared Class II medical device. Plain and simple. But, the Hello Heart app, the part that gives you personalized coaching and AI-driven analysis of your data, is not FDA-cleared. This is a fundamental difference for anyone buying or recommending the service. The blood pressure numbers coming from the cleared monitor are reliable. However, the interpretations, advice, and predictions the app’s AI generates haven’t been put through the same regulatory gauntlet as a diagnostic SaMD. The app is acting more like a wellness platform or a clinical decision support tool. It’s there to give users information and encourage them to make better choices, not to give them a formal diagnosis. This setup proves that having an “FDA-cleared” piece of hardware in your system doesn’t automatically grant that status to the software and AI it connects to.
The Buyer’s Imperative: Due Diligence Beyond the Headline
For anyone in procurement or doing clinical evaluations, the “FDA-cleared” label is just the start of your investigation. When you’re looking at any cardiovascular AI tech, especially in the monitoring and diagnostics market, you need to be asking pointed questions:
- What specific component(s) are FDA-cleared? Are we talking about the hardware, one specific algorithm, or the whole software platform?
- What are the exact Indications for Use (IFU) for each clearance? The IFU tells you exactly what the device or algorithm is supposed to do, and just as important, what it’s not supposed to do.
- What is the predicate device? Knowing which older device they used for the 510(k) comparison can tell you a lot about the scope and limits of the new clearance. Understanding FDA Predicate Devices
- Is the AI model subject to a Predetermined Change Control Plan (PCCP)? This is a huge deal for any adaptive AI/ML. A PCCP lets the company make pre-approved changes to the model without filing a whole new submission every time. Without one, every time the cardiac AI model retrains on new data, they might need a new 510(k), which is completely unscalable.
- What is the classification of the AI? Clinical Decision Support (CDS) vs. Diagnostic AI? There’s a world of difference in regulation. If your AI says ‘probable HFpEF, recommend referral,’ it’s likely CDS. If it flat out says ‘HFpEF confirmed,’ it’s a regulated diagnostic device and the evidence required is much higher. The whole field of AI heart health is moving fast, with constant changes in AI prediction methods and what counts as good clinical validation. The gap is getting wider between general-purpose LLMs trying to do cardiac triage and specialized platforms built for actual diagnostic work. For those specialized platforms, regulatory clarity is a clinical necessity, not just a marketing talking point.
Conclusion
In the crowded and fast-growing cardiac AI market, companies love to wave their FDA clearances around as proof of credibility and safety. But the technology is sophisticated, and we need to understand what those clearances really mean. By digging into the details, the scope of clearance for the hardware, the specific algorithms, and the software platforms, buyers can make smart decisions that fit their clinical needs, meet their regulatory duties, and protect their patients. The stories of AliveCor, Eko Health, and Hello Heart all show the same thing: “FDA-cleared” isn’t a blanket approval, it’s a precise regulatory term that demands scrutiny to understand the true capabilities and limits of any cardiac AI solution.
Frequently Asked Questions
What does ‘FDA-cleared’ mean for cardiac AI products, and is it a blanket approval?
‘FDA-cleared’ is not a blanket approval for an entire product or platform in cardiac AI. It often refers to clearance for specific components, such as a hardware device, a particular diagnostic algorithm, or a broader software platform. These clearances are distinct, often obtained through separate submissions, and each has its own scope and limitations.
If a cardiac AI product’s hardware is FDA-cleared, does that automatically mean its AI algorithms are also cleared?
No, an FDA-cleared hardware device does not automatically confer clearance status on its associated AI algorithms or software. The AI algorithm interpreting signals may require its own separate clearance, particularly if it performs a diagnostic function. Buyers must understand that the hardware and specific analytical algorithms often have their own defined scope of clearance.
What is the distinction between FDA clearance for hardware and for AI algorithms in cardiac monitoring?
FDA clearance for hardware typically covers the device’s ability to acquire data, such as an ECG signal or heart sounds. Clearance for AI algorithms, especially those classified as Software as a Medical Device (SaMD), pertains to their ability to interpret that data and provide diagnostic information, such as detecting specific cardiac conditions. These are often distinct clearances, each with specific indications for use.
How can buyers ensure they understand the full scope of FDA clearance for a cardiac AI product?
Buyers must look beyond the headline claim of ‘FDA-cleared’ to understand the granular details of each clearance. This involves identifying precisely what has been cleared (e.g., hardware, a specific algorithm, or a software platform) and its specific indications for use. This due diligence is crucial for accurate risk assessment and ensuring patient safety.
